Latham & Watkins Advises on Halozyme Therapeutics, Inc.’s Upsized US$1.3 Billion Convertible Senior Notes Offering

Halozyme Therapeutics, Inc. (Nasdaq: HALO) (the company), announced the pricing of US$1.3 billion aggregate principal amount of 1.5% convertible senior notes due 2033. The offering size was increased from the previously announced offering size of US$1.05 billion aggregate principal amount of notes. The company also granted a 13-day option to the initial purchasers to purchase up to an additional US$200 million aggregate principal amount of the convertible notes. The convertible notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The company expects to close the offering on September 22, 2026, subject to the satisfaction of various customary closing conditions.

Latham & Watkins LLP represents the initial purchasers in the offering with a Capital Markets team led by partners Cheston Larson, Greg Rodgers, Michael Sullivan, and Andrew Blumenthal, with associates Andrew Bentz, Sterling Swift, Steve Hess, and Katie Raya. Advice was also provided on derivatives matters by partner Reza Mojtabaee-Zamani, with associates Sloan Ungerman and Daniel Weiss; on FDA regulatory matters by counsel Chad Jennings; on healthcare regulatory matters by Betty Pang; on intellectual property matters by partner Darryl Steensma, with associates Arun Mohan and Andrew Wang; and on tax matters by partner Bora Bozkurt, with associate Jack Santoro.